Review
doi: 10.1016/j.gtc.2010.08.012.
New pharmacologic therapies in chronic hepatitis B
Affiliations
- PMID: 20951923
- DOI: 10.1016/j.gtc.2010.08.012
Item in Clipboard
Review
New pharmacologic therapies in chronic hepatitis B
Gastroenterol Clin North Am.
2010 Sep.
Abstract
Approximately 350 million persons worldwide are chronically infected with hepatitis B, which can result in cirrhosis, liver failure, and hepatocellular carcinoma. Currently, 2 interferons and 5 nucleos(t)ide analogues have been approved for the treatment of chronic hepatitis B (CHB). This article discusses the mechanisms of action, pharmacokinetics, optimal dose, clinical efficacy, and side effects of medications used for the treatment of CHB.
Copyright © 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Chronic hepatitis B: back to the future with HBsAg.Expert Rev Anti Infect Ther. 2009 Aug;7(6):633-6. doi: 10.1586/eri.09.57. Expert Rev Anti Infect Ther. 2009. PMID: 19681689 No abstract available.
-
What is the optimal therapy for chronic hepatitis B?Minerva Med. 2001 Dec;92(6):431-4. Minerva Med. 2001. PMID: 11740431 Review.
-
Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:171-82. doi: 10.1111/j.1365-2036.2007.03481.x. Aliment Pharmacol Ther. 2007. PMID: 18081660 Review.
-
Update of chronic hepatitis B.Curr Opin Gastroenterol. 2011 May;27(3):217-23. doi: 10.1097/MOG.0b013e32834595b5. Curr Opin Gastroenterol. 2011. PMID: 21423004 Review.
-
Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.Antivir Ther. 2010;15(3 Pt B):471-5. doi: 10.3851/IMP1552. Antivir Ther. 2010. PMID: 20516567 Review.
Cited by
-
Chronic hepatitis B: New potential therapeutic drugs target.World J Virol. 2022 Jan 25;11(1):57-72. doi: 10.5501/wjv.v11.i1.57. World J Virol. 2022. PMID: 35117971 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
